• Medicus Pharma reported results from a pre-specified expanded Phase 2 analysis of SKNJCT-003 testing its doxorubicin microneedle array for nodular basal cell carcinoma, adding to previously disclosed topline data from broader randomized enrollment.
• Updated review showed a clearer dose-response signal, with higher-dose treatment delivering the strongest overall clearance pattern versus device-only control.
• Separation versus control strengthened over follow-up, supporting a drug-driven effect rather than a short-lived device response.
• Safety profile remained favorable, with no drug-related serious adverse events reported and no signs of systemic doxorubicin toxicity.
• Dataset is being positioned to support end-of-Phase 2 talks with FDA on a registration path, including selection of dose and target patient population.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605060730PRIMZONEFULLFEED9713462) on May 06, 2026, and is solely responsible for the information contained therein.